vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.17M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
VTVT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
vTv Therapeutics Inc.NASDAQ: VTVT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $24.13M, compared with -$6.22M a year earlier. Trailing-twelve-month net income was $918K. Over 3 fiscal years it compounded at +17.5% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$14.44M (-53.5%) for the fiscal year ending Dec 2026, a slowdown from the +36.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $24.13M+438.1% QoQ
- Last fiscal yearDec 2025
- -$31.08M+36.9% YoY
- LTMMar 2026
- $918K+104.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +488.2% | +63.3% | -424.9 pp |
| 1 year | +36.9% | -53.5% | -90.4 pp |
| 3-year CAGR | +17.5% | +6.4% | -11.1 pp |
| 5-year CAGR | -4.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (31.08M) USD
- Year-over-year change
- -36.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.08M) | -36.9% |
| FY2024 | 2024-12-31 | (22.71M) | -12.1% |
| FY2023 | 2023-12-31 | (20.25M) | -5.7% |
| FY2022 | 2022-12-31 | (19.16M) | -8.1% |
| FY2021 | 2021-12-31 | (17.73M) | — |
Net Income vs competitors
How VTVT compares with its peers on the latest reported figures
- VTVT's LTM Mar 2026 net income of $918K is the smallest of the 9 companies compared; the peer median is $35.9M.
- Its year-over-year change of +104.2% is the 4th highest of 9, against a peer median of +1.6%.
- Net income amounts to 2.5% of revenue for VTVT, versus a peer median of 617.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $12.49B | +128201.2% | -23.6% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $21.24M | +1.5% | +4.7% | — | |
| LTM Mar 2026 | $918K | +104.2% | +17.5% | 2.5% | |
| Peer median (excluding VTVT) | $35.9M | +1.6% | -3.7% | 617.5% | |
Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.73M) | (19.16M) | (20.25M) | (22.71M) | (31.08M) |
| Depreciation & Amortization | 89K | 92K | 90K | 89K | 16K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.36M | 0 | 1.58M | 2.76M | 3.78M |
| Change in Working Capital | 35K | 5.39M | 4.39M | (5.44M) | 1.89M |
| Accounts Receivables | 101K | (116K) | 71K | 40K | 0 |
| Inventory | (889K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.83M | (856K) | 2.93M | 0 | 1.53M |
| Other Working Capital | (1.01M) | 6.36M | 1.39M | (5.48M) | 362K |
| Other Non-Cash Items | (4.06M) | (1.56M) | (4.89M) | (10K) | 142K |
| Operating Cash Flow | (19.31M) | (15.25M) | (19.08M) | (25.31M) | (25.26M) |
| Capital Expenditures | 0 | (21K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 4.4M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 4.4M | 0 | 0 |
| Other Investing Activities | 0 | 0 | (4.4M) | 0 | 0 |
| Investing Cash Flow | 0 | (21K) | 4.4M | 0 | 0 |
| Debt Repayment | 172K | (808K) | (33K) | (191K) | (392K) |
| Common Stock Issued | 26.76M | 14.79M | 12.03M | 52.8M | 77.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47K | 0 | 0 | 0 | 341K |
| Financing Cash Flow | 26.98M | 13.98M | 12M | 52.61M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.67M | (1.29M) | (2.68M) | 27.3M | 52.19M |
| Free Cash Flow | (19.31M) | (15.27M) | (19.08M) | (25.31M) | (25.26M) |
vTv Therapeutics Inc.
NASDAQ:VTVT
Intrinsic Alpha fair value
Locked
Current Price
$16.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.